NOVAN Nitric Oxide-Based Medicine
We use our proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs.
Press Releases
-
April 30, 2020
Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
-
April 20, 2020
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
-
April 3, 2020
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
